Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

Clostridium difficile is the most common cause of nosocomial diarrhea in acute-care settings. Until now, the two available therapies for C. difficile-associated diarrhea (CDAD), vancomycin and ...

[31] The difference between the resistance site (the β' subunit of the core enzyme) and the antibiotic binding site (the σ subunit) may be explained by the close physical proximity of the two ...

Study finds underutilization of fidaxomicin, a recommended treatment for C. diff infection, despite increased use in hospitals.

The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, ...

They looked at two different dosages of the drug, 200 milligrams and 400 milligrams, which were administered twice-daily; the team compared those results with 125 milligrams of the antibiotic ...

The product is based on purified Firmicutes bacterial spores delivered in an oral capsule that is designed to encourage the regrowth of healthy bacteria after antibiotic treatment for C.

Q: I was sick for months with debilitating pain, extreme weight loss, fatigue and loss of appetite. I was diagnosed with C. diff related to an abdominal surgery. I'm being ...

Fecal microbiota transplants, or FMTs, are a magic bullet for patients with recurring infections from Clostridioides ...

Researchers have found that a history of repeated antibiotic use causes defects in the normally protective mucus barrier of the gut, due to antibiotic-driven alterations in the microbiota.

Resistance to antibiotics has led to one million worldwide deaths each year since 1990, for a total of 36 million. It is expected to cause more than 39 million more fatalities by 2050 — three ...

More than 39 million people could die of antibiotic-resistant infections between now and 2050, according to a study published Monday in The Lancet. The authors of the study forecast a nearly 70 ...